Latest Breaking News On - Javelin pharmaceuticals inc hospira - Page 1 : comparemela.com

Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)

Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans - Seelos Therapeutics (NASDAQ:SEEL)

A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans.

Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the.

Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

- Acadia Healthcare is the Largest Stand-Alone Behavioral Health Company in the United States Operating a Network of Nearly 240 Behavioral Health Facilities in 39 States and Puerto Rico NEW YORK,. | September 13, 2022